OK so Christine Brown is presenting the first abstract on the first cohort dosed with CLTX.

A team member in Christine's team called Maryam Aftabizadeh is presenting the second abstract on the mechanism of how CLTX recognises GBM cells.

Below is taken from the City of Hope website. Bold and underline added for emphasis.

"

Maryam Aftabizadeh

Maryam AftabizadehRole:Staff Scientist

Maryam Aftabizadeh, Ph.D., earned her B.S. in biology in Tehran, Iran. Dr. Aftabizadeh moved to Germany to join a postgraduate program at RWTH Aachen, one of Germany’s Universities of Excellence, where she completed her Ph.D. in biochemistry and molecular cell biology. To pursue her interest in cancer biology and immunology, she joined the Department of Immuno-Oncology at City of Hope to work with Hua Yu, Ph.D., and, afterward, with a desire to understand the role of the tumor microenvironment in growth and progression of GBM, she joined the lab of Marcin Kortylewski, Ph.D., in the same department. She joined Dr. Brown’s lab as a staff scientist. Her project is concerned with, but not limited to, designing and executing immunochemical studies including immunohistochemistry, immunofluorescence and mass cytometry (CyTOF), coupled with analyses using high dimensional imaging software to profile immune cell infiltrates in GBM tumors. Dr. Aftabizadeh’s goals are to understand and surmount barriers limiting application of CAR T cell immunotherapy to glioblastoma and other primary and metastatic brain tumors. These barriers include the immunosuppressive microenvironment, T cell persistence and exhaustion and tumor antigen escape.

Maryam's got something to present at the SNO about how CLTX binds to GBM. Wonder what it will be?